Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte (VCYT) announced new data for the company’s Decipher urologic cancer tests to be presented at the 2022 ASCO GU Symposium

Click to view original post